Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct;13(10):12-16.
Epub 2020 Oct 1.

A Retrospective Registry Study Evaluating the Long-Term Efficacy and Safety of Superficial Radiation Therapy Following Excision of Keloid Scars

Brian Berman  1   2   3   4   5 , Mark S Nestor  1   2   3   4   5 , Michael H Gold  1   2   3   4   5 , David J Goldberg  1   2   3   4   5 , Eduardo T Weiss  1   2   3   4   5 , Isabelle Raymond  1   2   3   4   5
Affiliations
Review

A Retrospective Registry Study Evaluating the Long-Term Efficacy and Safety of Superficial Radiation Therapy Following Excision of Keloid Scars

Brian Berman et al. J Clin Aesthet Dermatol. 2020 Oct.

Abstract

BACKGROUND: Surgical treatment of keloid scars is associated with an approximately 70% recurrence rate at the excision site. OBJECTIVE: We sought to assess keloid recurrence rates when superficial radiation therapy (SRT) was applied following surgical excision. METHODS: Medical records were reviewed of subjects treated for keloid scars followed by SRT (SRT-100™; Sensus Healthcare, Boca Raton, Florida) using a biologically effective dose (BED) of 30Gy and for whom the required retrospective data was available. Eligible subjects (N=61) were treated for 96 keloid scars with SRT. Subjects were male (48%) and female (52%) with a mean age of 38.87 years. Subjects were treated for ≥1 keloid scars following removal by sutured excision (93%) or tangential excision with secondary intention technique (7%). Almost all subjects (98%) received BED 30Gy with irradiation scheme of three 6Gy SRT treatments on Days 1, 2 and 3 following surgery. Mean energy of 100KV (73%) or 70KV (27%) were applied. RESULTS: Ten treated keloidectomy sites (10.4%) had recurrences (i.e., presence of any new tissue growth on the surgical scar) within 12 months increasing to 11 (12.7%) at 18 months. Kaplan-Meier survival probability cure rate was 85.6% from 24 months post-SRT treatment onwards. Transient hyperpigmentation was the most frequent adverse event and there were no malignancies in the treatment area during follow-up evaluations. CONCLUSIONS: SRT with a BED value of 30 Gy delivered to keloidectomy excision sites immediately following excision was well-tolerated and resulted in markedly fewer long-term recurrences than reported following keloidectomy alone. Most keloid scar recurrences occurred within one year. There were no malignancies during follow-up evaluations.

Keywords: Keloids; keloid scars; recurrence rate; superficial radiation therapy.

PubMed Disclaimer

Conflict of interest statement

FUNDING:This study was sponsored by Sensus Healthcare, Boca Raton, Florida. DISCLOSURES:Dr. Berman is a consultant and speaker for Sensus Healthcare. Dr. Nestor is a consultant, speaker, and member of the Advisory Board for Sensus Healthcare. Drs. Gold and Goldberg are speakers for Sensus Healthcare. Dr. Raymond is a full-time employee of and owns shares in Sensus Healthcare. Dr. Weiss has no relevant conflicts to disclose.

Figures

FIGURE 1.
FIGURE 1.
Example of clinically significant recurrence: A) pre-surgery/SRT and; B) follow-up post-SRT; silicon scar gel was recommended at the six-month follow-up visit
FIGURE 2.
FIGURE 2.
Example of non-clinically significant keloid recurrence: A) prior to excision and SRT and; B) 19 months post-SRT. Patient received an intralesional corticosteroid and topical silicone gel at the last follow-up visit
See this image and copyright information in PMC

References

    1. Berman B, Maderal A, Raphael B. Keloids and hypertrophic scars: pathophysiology, classification, and treatment. Dermatol Surg. 2017;43:S3–S18. - PubMed
    1. Atiyeh BS, Costagliola M, Hayek SN. Keloid or hypertrophic scar: the controversy: review of the literature. Ann Plast Surg. 2005;54:676–680. - PubMed
    1. Brown JJ, Bayat A. Genetic susceptibility to raised dermal scarring. Br J Dermatol. 2009;161:8–18. - PubMed
    1. Glass DA., 2nd Current understanding of the genetic causes of keloid formation. J Investig Dermatol Symp Proc. 2017;18:S50–53. - PubMed
    1. Jones ME, McLane J, Adenegan R et al. Advancing keloid treatment: a novel multimodal approach to ear keloids. Dermatol Surg. 2017;43:1164–1169. - PubMed

LinkOut - more resources